Recently, Chen et.al (2024) found that while the presence of bone metastasis is a negative prognostic factor for EGFR-mutated lung cancer patients, the addition of antiangiogenic therapy and denosumab, with sequential osimertinib can improve survival outcomes [16]. This evidence concerns the gene EGFR and bone metastasis.